MA55381A - Pyridazinones et leurs procédés d'utilisation - Google Patents

Pyridazinones et leurs procédés d'utilisation

Info

Publication number
MA55381A
MA55381A MA055381A MA55381A MA55381A MA 55381 A MA55381 A MA 55381A MA 055381 A MA055381 A MA 055381A MA 55381 A MA55381 A MA 55381A MA 55381 A MA55381 A MA 55381A
Authority
MA
Morocco
Prior art keywords
pyridazinones
methods
Prior art date
Application number
MA055381A
Other languages
English (en)
Inventor
Michael Broxson
Gal Marie-Francoise Yveline Coeffet-Le
Matthew H Daniels
Jean-Christophe P Harmange
Mark W Ledeboer
Peter H Mundel
John Francis Reilly
Liron Walsh
Amy Kieu Duyen Westerling-Bui
Maolin Yu
Original Assignee
Goldfinch Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Goldfinch Bio Inc filed Critical Goldfinch Bio Inc
Publication of MA55381A publication Critical patent/MA55381A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA055381A 2019-03-20 2020-03-18 Pyridazinones et leurs procédés d'utilisation MA55381A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962821178P 2019-03-20 2019-03-20

Publications (1)

Publication Number Publication Date
MA55381A true MA55381A (fr) 2022-01-26

Family

ID=72519163

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055381A MA55381A (fr) 2019-03-20 2020-03-18 Pyridazinones et leurs procédés d'utilisation

Country Status (11)

Country Link
US (1) US20220152031A1 (fr)
EP (1) EP3941475A4 (fr)
JP (2) JP7571039B2 (fr)
CN (2) CN120393027A (fr)
AU (2) AU2020240059B2 (fr)
CA (1) CA3132580A1 (fr)
IL (2) IL286481B2 (fr)
MA (1) MA55381A (fr)
MX (2) MX2021011316A (fr)
SG (1) SG11202109568TA (fr)
WO (1) WO2020191056A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018334290A1 (en) 2017-09-18 2020-04-02 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
IL281438B2 (en) * 2018-09-18 2023-12-01 Goldfinch Bio Inc Pyridazinones and methods of use thereof
IL286481B2 (en) * 2019-03-20 2025-12-01 Goldfinch Bio Inc Pyridazinones and methods of use thereof
MX2021012310A (es) 2019-04-11 2021-11-12 Goldfinch Bio Inc Formulación de secado por aspersión de un inhibidor de trpc5 de piridazinona.
IL299623A (en) * 2020-07-03 2023-03-01 Wuhan Ll Science & Technology Development Co Ltd Heterocyclic compound and its use
CN117940417A (zh) * 2021-09-10 2024-04-26 南京明德新药研发有限公司 卤素取代的哒嗪酮类化合物及其应用
CN114235972B (zh) * 2021-10-28 2023-08-22 乳源东阳光药业有限公司 一种测定利格列汀杂质rbp-1含量的方法
KR20240149461A (ko) 2022-01-18 2024-10-14 메이즈 테라퓨틱스, 인코퍼레이티드 Apol1 저해제 및 사용 방법
WO2024027752A1 (fr) * 2022-08-05 2024-02-08 武汉朗来科技发展有限公司 Composition pharmaceutique comprenant un composé hétérocyclique, procédé de préparation associé et utilisation correspondante
CN118834210A (zh) 2023-04-25 2024-10-25 中国科学院上海药物研究所 哒嗪酮类trpc4/5抑制剂及其用途
WO2024249254A2 (fr) * 2023-05-26 2024-12-05 Maze Therapeutics, Inc. Procédés d'utilisation d'inhibiteurs d'apol1

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2945857A (en) * 1955-05-06 1960-07-19 Monsanto Chemicals Pyridazinones
GB8901423D0 (en) * 1989-01-23 1989-03-15 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
GB9015764D0 (en) * 1990-07-18 1990-09-05 Fujisawa Pharmaceutical Co Pyrazolopyridine compound and processes for preparation thereof
CA2099743A1 (fr) * 1992-07-02 1994-01-03 Akihiko Ishida Derives de la pyridazinone et procedes pour leur preparation
CA2180253A1 (fr) * 1993-12-29 1995-07-06 Atsushi Akahane Compose pyrazolopyridine antagoniste de l'adenosine
JPH09216883A (ja) * 1996-02-09 1997-08-19 Fujisawa Pharmaceut Co Ltd ピラゾロピリジン化合物および該化合物を含有する医薬
AUPQ441499A0 (en) * 1999-12-02 2000-01-06 Fujisawa Pharmaceutical Co., Ltd. Novel compound
AUPQ969800A0 (en) * 2000-08-28 2000-09-21 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine compound and pharmaceutical use thereof
WO2003057689A1 (fr) * 2002-01-02 2003-07-17 Fujisawa Pharmaceutical Co., Ltd. Composes aminopyrimidine, procedes de preparation de ces composes et compositions pharmaceutiques les contenant
WO2004022540A2 (fr) * 2002-09-06 2004-03-18 Fujisawa Pharmaceutical Co., Ltd. Compose de pyridazinone et son utilisation pharmaceutique
AU2003901647A0 (en) * 2003-04-04 2003-05-01 Fujisawa Pharmaceutical Co., Ltd. Novel Condensed Furan Compounds and Pharmaceutical Use Thereof
JP2007524673A (ja) * 2004-01-23 2007-08-30 アムジエン・インコーポレーテツド バニロイド受容体リガンドと治療におけるその使用
BRPI0517418A (pt) * 2004-10-13 2008-10-07 Merck & Co Inc composto, composição farmacêutica, e, métodos para antagonismo de atividade do receptor de cgrp em um mamìfero, para tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca ou cefalgia, e de tratamento ou prevenção de dores de cabeça de enxaqueca, cefalgias, e dores de cabeça
JP2008528613A (ja) * 2005-01-25 2008-07-31 ニューロジェン・コーポレーション 置換ピリダジニル−及びピリミジニル−キノリン−４−イルアミン類縁体
DE602006011363D1 (de) * 2005-12-01 2010-02-04 Hoffmann La Roche Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer
US20090227588A1 (en) * 2005-12-05 2009-09-10 Roman Wolfgang Fleck Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007061963A1 (de) * 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
EP2265601B1 (fr) * 2008-03-13 2012-02-01 Bristol-Myers Squibb Company Dérivés de la pyridazine inhibiteurs du facteur xia
JP2011515401A (ja) * 2008-03-20 2011-05-19 アムジエン・インコーポレーテツド オーロラキナーゼモジュレーターおよび使用方法
DE102008062826A1 (de) * 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
US20170146554A1 (en) * 2009-06-10 2017-05-25 Masanori Hara Method for test on diabetic nephropathy
GB201222711D0 (en) * 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
TW201444844A (zh) * 2013-03-14 2014-12-01 Hydra Biosciences Inc 經取代之黃嘌呤及使用其之方法
MA36055B1 (fr) * 2013-06-27 2015-12-31 Univ Mohammed V Souissi Dérivés des pyridazin-3(2h)-ones, préparation , activités pharmacologiques et biologiques
EP2881390A1 (fr) * 2013-12-04 2015-06-10 Sanofi Dérivés de thienométhylpipérazine en tant qu'inhibiteurs d'époxyde-hydrolase soluble
CN103772352B (zh) * 2014-01-16 2017-01-18 四川百利药业有限责任公司 哒嗪酮类衍生物及其制备方法和用途
WO2016023830A1 (fr) * 2014-08-11 2016-02-18 Hydra Biosciences, Inc. Dérivés de pyrido[2,3-d]pyrimidine-2,4(1h,3h)-dione
AU2018334290A1 (en) * 2017-09-18 2020-04-02 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
SI3788040T1 (sl) * 2018-04-30 2023-07-31 Ribon Therapeutics Inc. Piridazinoni kot zaviralci parp7
WO2019236625A1 (fr) * 2018-06-04 2019-12-12 Ohio State Innovation Foundation Activateurs de l'eaat2 et leurs méthodes d'utilisation
IL281438B2 (en) * 2018-09-18 2023-12-01 Goldfinch Bio Inc Pyridazinones and methods of use thereof
IL286481B2 (en) * 2019-03-20 2025-12-01 Goldfinch Bio Inc Pyridazinones and methods of use thereof

Also Published As

Publication number Publication date
SG11202109568TA (en) 2021-10-28
US20220152031A1 (en) 2022-05-19
IL286481B2 (en) 2025-12-01
CA3132580A1 (fr) 2020-09-24
CN113939295A (zh) 2022-01-14
CN113939295B (zh) 2025-05-16
MX2025012087A (es) 2025-11-03
JP2022525506A (ja) 2022-05-17
JP2025020132A (ja) 2025-02-12
EP3941475A1 (fr) 2022-01-26
AU2020240059A1 (en) 2021-10-28
JP7571039B2 (ja) 2024-10-22
EP3941475A4 (fr) 2023-01-25
IL321764A (en) 2025-08-01
CN120393027A (zh) 2025-08-01
IL286481B1 (en) 2025-08-01
AU2026200453A1 (en) 2026-02-12
WO2020191056A8 (fr) 2021-09-30
AU2020240059B2 (en) 2025-10-23
MX2021011316A (es) 2021-10-13
WO2020191056A1 (fr) 2020-09-24
IL286481A (en) 2021-12-01

Similar Documents

Publication Publication Date Title
EP3941475A4 (fr) Pyridazinones et leurs procédés d'utilisation
EP3684364A4 (fr) Pyridazinones et leurs procédés d'utilisation
EP3852533A4 (fr) Pyridazinones et leurs procédés d'utilisation
EP4037695A4 (fr) Compositions oligonucléotidiques et leurs procédés d'utilisation
MA55890A (fr) Modulateurs de thr-beta et leurs procédés d'utilisation
EP3958872A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3790596A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
EP3775203A4 (fr) Compositions d'oligonucléotides et leurs procédés d'utilisation
MA55136A (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
MA54538A (fr) Inhibiteurs d'apol1 et leurs procédés d'utilisation
EP3968999A4 (fr) Inhibiteurs de fgfr et leurs procédés d'utilisation
MA55885A (fr) Chélateurs macrocycliques et leurs procédés d'utilisation
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
MA54261A (fr) Inhibiteurs de pcsk9 et leurs procédés d'utilisation
EP4022069A4 (fr) Arn circulaires modifiés et leurs procédés d'utilisation
EP3911640A4 (fr) Inhibiteurs de pcsk9 et leurs procédés d'utilisation
EP3790572A4 (fr) Variants du récepteur de l'activine de type iia et leurs procédés d'utilisation
MA55301A (fr) Inhibiteurs de protéine tyrosine phosphatase et leurs procédés d'utilisation
MA55025A (fr) Anticorps anti-trem2 et leurs procédés d'utilisation
EP3846808A4 (fr) Inhibiteurs de papd5 et leurs procédés d'utilisation
EP3893917A4 (fr) Compositions d'il-15 et leurs procédés d'utilisation
MA56457A (fr) Modulateurs de hsd17b13 et leurs procédés d'utilisation
MA51837A (fr) Inhibiteurs de l'arginase et leurs procédés d'utilisation
EP3688373A4 (fr) Brûleurs et leurs procédés d'utilisation
EP4034605A4 (fr) Compositions de polissage et leurs procédés d'utilisation